Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Brent who wrote (20852)	4/20/1999 12:02:00 PM
From: VLAD	Read Replies (3) \| Respond to of 23519

Brent, You got that wrong! The shorts have latched on to Vivus like a pit bull early last year and still have not released their grip. Viagra, and an incompetent management team gave them little reason to worry. IMO the fact that Vivus will show a profit equiv to the milestones in a quarter when sales will suck tells me that there is a lot of profit POTENTIAL once Europe is launched and Lee finally gets his head out of hit butt and signs a domestic partner. Think of what Q2 can look like profit wise with another $4M milestone, Astra/Zeneca launching MUSE in early May and Vivus having a domestic partner who would launch MUSE domestically in early June. If all that clicked then also think what the profit potential would be for the rest of 1999 as more international launches take place. For a small biotech stock with some other VERY promising R&D for future products (especially female SD cream) there is NO F###### WAY this stock should be trading at 4. It is said that a stock trades at its potential looking forward 6 to 12 months out maybe more. If that theory holds correct we should be at about 20 today. Yes product sales for Q1 will suck but considering that nobody is marketing it in the USA and Europe still has not been launched what do you expect?